ShopSpell

Reverse Transcriptase Inhibitors in HIV/AIDS Therapy [Paperback]

$223.99     $249.99   10% Off     (Free Shipping)
100 available
  • Category: Books (Medical)
  • ISBN-10:  1617376957
  • ISBN-10:  1617376957
  • ISBN-13:  9781617376955
  • ISBN-13:  9781617376955
  • Publisher:  Humana
  • Publisher:  Humana
  • Pages:  528
  • Pages:  528
  • Binding:  Paperback
  • Binding:  Paperback
  • Pub Date:  01-Mar-2010
  • Pub Date:  01-Mar-2010
  • SKU:  1617376957-11-SPRI
  • SKU:  1617376957-11-SPRI
  • Item ID: 100875650
  • List Price: $249.99
  • Seller: ShopSpell
  • Ships in: 5 business days
  • Transit time: Up to 5 business days
  • Delivery by: Nov 30 to Dec 02
  • Notes: Brand New Book. Order Now.

A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.A magisterial survey of all aspects of the reverse transcriptase inhibitors (RTIs) used to treat HIV/AIDS, including drug discovery, pharmacology, development of drug resistance, toxicity, and prevention of mother-to-child transmission of HIV/AIDS. The authors synthesize our current understanding of the role of reverse transcriptase in the viral life cycle, describe the discovery and development of eight nucleoside and nucleotide analogs that represent milestones in treatment history, and thoroughly discuss the question of toxicity and resistance to this class of drugs. They also address three non-nucleoside RTIs and their pharmacokinetics and comparative clinical efficacy, new RTIs currently under development, and the impact of approved agents on treatment, in general, and on vertical transmission in the developing world.Structural Studies on HIV Reverse Transcriptase Related to Drug DiscoveryDavid K. Stammers and Jingshan RenZidovudine, Lamivudine, and AbacavirMonica Carten and Harold KesslerStavudine, Didanosine, and ZalcitabineGail Skowron, Sapna Chowdhry, and Michael R. StevensEmtricitabineGail Skowron, Jeffrey Bratberg, and Rudi PauwelsNucleolÓ*

Add Review